Ann Dermatol.  2010 Aug;22(3):300-306. 10.5021/ad.2010.22.3.300.

Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients

• Choi WJ
• Park EJ
• Kwon IH
• Kim KH
• Kim KJ

• KMID: 2265363
• DOI: http://doi.org/10.5021/ad.2010.22.3.300

Abstract

BACKGROUND
Previous studies have shown a possible association between psoriasis and cardiovascular risk factors.
OBJECTIVE
We wanted to study the association between psoriasis and cardiovascular risk factors, including metabolic syndrome.
METHODS
We determined the relationship of psoriasis with the cardiovascular risk factors, metabolic syndrome and cardiovascular disease. For the proper level of low-density lipoprotein (LDL) cholesterol, we calculated the proportion of psoriasis patients who needed lifestyle changes or drug therapy.
RESULTS
This study included 197 patients with psoriasis and 401 controls. We found a higher prevalence of metabolic syndrome (17.8%, p=0.021), cardiovascular disease (4.6%, p=0.044), hypertension (32.5%, p=0.000) and hyperlipidemia (22.3%, p=0.025) in patients with psoriasis, as compared with that of the controls. To maintain proper LDL levels, 25.3% of the psoriasis patients needed lifestyle changes and 11.7% needed drug therapy.
CONCLUSION
Our results demonstrate a possible association between psoriasis and cardiovascular diseases and their risk factors (metabolic syndrome, hypertension and hyperlipidemia) in Korean patients. We also demonstrated that a substantial portion of patients with psoriasis need lifestyle changes and drug therapy to prevent cardiovascular events. Further studies will be necessary to establish the association and causality between psoriasis and the cardiovascular risk factors.

Keyword

Cardiovascular risk factor; Framingham risk score; Metabolic syndrome; Psoriasis

MeSH Terms

Cardiovascular Diseases
Cholesterol
Humans
Hyperlipidemias
Hypertension
Life Style
Lipoproteins
Prevalence
Psoriasis
Risk Factors
Cholesterol
Lipoproteins

Reference

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999. 41:401–407.

2. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005. 352:1899–1912.

3. Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol. 2009. 160:1–7.

4. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol. 2006. 24:1 Suppl 40. S72–S78.

5. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol. 2000. 9:1–10.

6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995. 32:982–986.

7. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008. 216:152–155.

8. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999. 41:S7–S12.

9. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999. 20:437–449.

10. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med. 2005. 5:124–139.

11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005. 366:1059–1062.

12. Bae SJ, Lee MK. Definition and diagnosis of the metabolic syndrome. J Korean Med Assoc. 2005. 48:1157–1164.

13. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001. 286:180–187.

14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.

15. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J. 2001. 22:1226–1234.

16. Libby P. Inflammation in atherosclerosis. Nature. 2002. 420:868–874.

17. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004. 18:180–183.

18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002. 347:1557–1565.

19. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009. 29:424–430.

20. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008. 45:114–116.

21. Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006. 154:345–352.

22. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009. 41:199–204.

23. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes. 2007. 56:499–505.

24. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005. 141:1527–1534.

25. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004. 19:225–230.

26. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007. 56:629–634.

27. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010. 90:23–26.

28. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007. 87:506–509.

29. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007. 21:1330–1332.

30. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007. 157:68–73.

31. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol. 2009. 23:1311–1315.

32. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009. 145:700–703.

33. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004. 51:563–569.

34. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002. 136:157–160.

35. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991. 303:276–282.

36. Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol. 2010. 130:917–919.